Highlights
Patients with ST-elevation myocardial infarction-related cardiogenic shock (STEMI-CS) who meet the DanGer Shock (DGS) trial eligibility criteria (DGS-like) exhibit significantly lower mortality at 180 days when treated with a microaxial flow pump (mAFP) compared to those who do not (62.5% vs. 72.0%).
The survival advantage of the DGS-like profile is evident as early as 30 days, with an all-cause mortality rate of 48.4% compared to 70.2% in the DGS-unlike cohort.
